Nanovectorization of Prostate Cancer Treatment Strategies: A New Approach to Improved Outcomes

Omabe, Kenneth Nwobini; Paris, Clément; Taïeb, David; Rocchi, Palma

doi:10.3390/pharmaceutics13050591

Cited by 11 publications

(8 citation statements)

References 154 publications

(199 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The treatment management involving castration came up with a success rate of 60%-70% depending on different criteria. A decrease in the success rate was observed with an increase in the secretion of adrenal androgen hormones in association with the evolution of upregulated or mutated androgen receptors (Qin W et al, 2017;Omabe K et al, 2021). At the developmental stage, prostate cancer relies on the androgenic hormones to proliferate.…”

Section: Novel Hormone Therapymentioning

confidence: 99%

Advances and development of prostate cancer, treatment, and strategies: A systemic review

Belkahla

Nahvi

Biswas

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

The most common type of cancer in the present-day world affecting modern-day men after lung cancer is prostate cancer. Prostate cancer remains on the list of top three cancer types claiming the highest number of male lives. An estimated 1.4 million new cases were reported worldwide in 2020. The incidence of prostate cancer is found predominantly in the regions having a high human development index. Despite the fact that considerable success has been achieved in the treatment and management of prostate cancer, it remains a challenge for scientists and clinicians to curve the speedy advancement of the said cancer type. The most common risk factor of prostate cancer is age; men tend to become more vulnerable to prostate cancer as they grow older. Commonly men in the age group of 66 years and above are the most vulnerable population to develop prostate cancer. The gulf countries are not far behind when it came to accounting for the number of individuals falling prey to the deadly cancer type in recent times. There has been a consistent increase in the incidence of prostate cancer in the gulf countries in the past decade. The present review aims at discussing the development, diagnostics via machine learning, and implementation of treatment of prostate cancer with a special focus on nanotherapeutics, in the gulf countries.

show abstract

Section: Novel Hormone Therapymentioning

confidence: 99%

Advances and development of prostate cancer, treatment, and strategies: A systemic review

Belkahla

Nahvi

Biswas

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…3 Meanwhile, this extra-prostatic metastasis and tumor heterogeneity also often result in unsatisfactory treatment by conventional radiotherapy. 4 Therefore, there is an urgent clinical need for a novel, highly effective, and highly specific treatment for PCa. 5,6 Prostate-specific membrane antigen (PSMA) is a specific target for prostate cancer and has been widely implicated in prostate cancer imaging and treatment in clinical settings.…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

In vitro and in vivo Evaluation of Folic Acid Modified DOX-Loaded 32P-nHA Nanoparticles in Prostate Cancer Therapy

Deng¹,

Wang²,

Zhou³

et al. 2023

IJN

View full text Add to dashboard Cite

Background: Prostate cancer (PCa) ranks second in the incidence of all malignancies in male worldwide. The presence of multiorgan metastases and tumor heterogeneity often leads to unsatisfactory outcomes of conventional radiotherapy treatments. This study aimed to develop a novel folate-targeted nanohydroxyapatite (nHA) coupling to deliver adriamycin (Doxorubicin, DOX), 32 P, and 99m Tc simultaneously for the diagnosis and treatment of prostate-specific membrane antigen (PSMA) positive prostate cancer. Methods: The spherical nHA was prepared by the biomimetic method and characterized. Folic acid (FA) was coupled to nHA with polyethylene glycol (PEG), and the grafting ratio of PEG-nHA and FA-PEG-nHA was determined by the thermogravimetric analysis (TGA) method. In addition, 32 P, 99m Tc, and DOX were loaded on nHA by physisorption. And the labeling rate and stability of radionuclides were measured by a γ-counter. The loading and release of DOX at different pH were determined by the dialysis method. Targeting of FA-PEG-nHA loaded with 99m Tc was verified by in vivo SPECT imaging. In vitro anti-tumor effect of 32 P/DOX-FA-PEG-nHA was assessed with apoptosis assay. The safety of the nano-drugs was verified by histopathological analysis. Results:The SEM images showed that the synthesized nHA was spherical with uniform particle size (average diameter of about 100nm). The grafting ratio is about 10% for PEG and about 20% for FA. The drug loading and the delayed release of DOX at different pH confirmed its long-term therapeutic ability. The labeling of 32 P and 99m Tc was stable and the labeling rate was great. SPECT showed that FA-PEG-nHA showed well in vivo tumor targeting and less damage to normal tissues. Conclusion: FA-targeted nHA loaded with 32 P, 99m Tc, and DOX may be a new diagnostic and therapeutic strategy for targeting PSMA-positive prostate cancer tumors, which may achieve better therapeutic results while circumventing the severe toxic side effects of conventional chemotherapeutic agents.

show abstract

“…Combination chemotherapy is a promising method for improving cancer treatment. However, clinical combination therapy is limited by the unique pharmacokinetics of the combined drugs, resulting in uneven drug distribution [ 28 , 29 ]. We established tumor-targeting NPs, combining FD binding to P-selectin-expressing tumors and TH targeting CD44-expressing tumors to reduce P-gp expression.…”

Section: Introductionmentioning

confidence: 99%

Targeting Tumor Cells with Nanoparticles for Enhanced Co-Drug Delivery in Cancer Treatment

et al. 2021

View full text Add to dashboard Cite

Gastric cancer (GC) is a fatal malignant tumor, and effective therapies to attenuate its progression are lacking. Nanoparticle (NP)-based solutions may enable the design of novel treatments to eliminate GC. Refined, receptor-targetable NPs can selectively target cancer cells and improve the cellular uptake of drugs. To overcome the current limitations and enhance the therapeutic effects, epigallocatechin-3-gallate (EGCG) and low-concentration doxorubicin (DX) were encapsulated in fucoidan and d-alpha-tocopherylpoly (ethylene glycol) succinate-conjugated hyaluronic acid-based NPs for targeting P-selectin-and cluster of differentiation (CD)44-expressing gastric tumors. The EGCG/DX-loaded NPs bound to GC cells and released bioactive combination drugs, demonstrating better anti-cancer effects than the EGCG/DX combination solution. In vivo assays in an orthotopic gastric tumor mouse model showed that the EGCG/DX-loaded NPs significantly increased the activity of gastric tumors without inducing organ injury. Overall, our EGCG/DX-NP system exerted a beneficial effect on GC treatment and may facilitate the development of nanomedicine-based combination chemotherapy against GC in the future.

show abstract

Nanovectorization of Prostate Cancer Treatment Strategies: A New Approach to Improved Outcomes

Cited by 11 publications

References 154 publications

Advances and development of prostate cancer, treatment, and strategies: A systemic review

Advances and development of prostate cancer, treatment, and strategies: A systemic review

In vitro and in vivo Evaluation of Folic Acid Modified DOX-Loaded 32P-nHA Nanoparticles in Prostate Cancer Therapy

Targeting Tumor Cells with Nanoparticles for Enhanced Co-Drug Delivery in Cancer Treatment

Contact Info

Product

Resources

About